To date, there is limited research on how the treatment durations of relatively newer classes of antidiabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase 4 inhibitors (DPP-4I), and sodium–glucose cotransporter 2 inhibitors (SGLT-2I), influence lung cancer prognosis. Here, GLP1R is linked to lung carcinoma.